FDA Accepts for Review Pegfilgrastim Biosimilar From Fresenius Kabi

May 28, 2020


Fresenius Kabi is hoping to position itself in the US biosimilar market.

Association Details Why BPCIA Should Stay Even If ACA Falls

May 27, 2020


The Association of Accessible Medicines (AAM), which supports biosimilar development, argues that even if the Affordable Care Act (ACA) is overturned by the Supreme Court later this year, the Biologics Price Competition and Innovation Act (BPCIA) is severable and should survive.

Models Show Switch to Bevacizumab, Rituximab Biosimilars Yields Millions in Savings

May 25, 2020


Cost savings are likely to occur should payers switch from originator bevacizumab or rituximab to their respective biosimilars, according to research from 2 studies presented at the Virtual 2020 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting.

Samsung Bioepis Reports Equivalency for Ranibizumab Biosimilar

May 23, 2020


Samsung Bioepis announced positiive trial results for its ranibizumab biosimilar (SB11).

Survey of Commercial Health Plans Finds Few Give Biosimilars Preferred Status

May 23, 2020


Compared with use of originator products, use of biosimilars in the United States is apparently still not a priority of commercial health plans, according to the results of a recent JAMA study.

Positive Messaging Can Boost Biosimilar Benefits Across Inflammatory Disease

May 16, 2020


Biosimilar developers can assuage some physician—and even patient—concerns through coordinated, evidence-based messaging.

Pharmacies Adapt in the Wake of Challenges Created by COVID-19, Panel Says

May 15, 2020


In light of the coronavirus disease 2019 (COVID-19) pandemic, pharmacies have implemented new strategies to ensure their patients continue to receive care, especially for those who have lost their insurance or have underlying conditions, speakers said this week during the Pharmacy Quality Alliance (PQA) 2020 Annual Meeting.

Consumers, Employers, and Prescription Drugs During COVID-19: A Q&A With Arxcel's Chris Robbins

May 12, 2020


How will coronavirus disease 2019 (COVID-19) affect prescription drug trends? The American Journal of Managed Care® (AJMC®) put questions to Chris Robbins, chief executive officer of Arxcel Consulting LLC, to review these subjects and more in a wrapup discussion after the Academy of Managed Care Pharmacy virtual meeting.

Proposed Bevacizumab Biosimilar for mCRC Found Noninferior to Reference Drug

May 08, 2020


A proposed bevacizumab biosimilar, BE1040V, was found to be noninferior to its reference product (Avastin) in terms of efficacy for the treatment of metastatic colorectal cancer (mCRC), according to a study published in Clinical Therapeutics.